A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial
Tekijät: Hague William M., Callaway Leonie, Chambers Jennifer, Chappell Lucy, Coat Suzette, de Haan-Jebbink Jiska, Dekker Marloes, Dixon Peter, Dodd Jodie, Fuller Maria, Gordijn Sanne, Graham Dorothy, Heikinheimo Oskari, Hennessy Annemarie, Kaaja Risto, Khong Teck Yee, Lampio Laura, Louise Jennie, Makris Angela, Markus Corey, Marschall Hanns-Ulrich, Middleton Philippa, Mol Ben W., Morris Jonathan, Newnham John P., Ovadia Caroline, Peek Michael, Shand Antonia, Stark Michael, Thornton Jim, Timonen Susanna, Walker Susan, Warrilow David, Williamson Catherine
Kustantaja: BMC
Julkaisuvuosi: 2021
Journal: BMC Pregnancy and Childbirth
Tietokannassa oleva lehden nimi: BMC PREGNANCY AND CHILDBIRTH
Lehden akronyymi: BMC PREGNANCY CHILDB
Artikkelin numero: ARTN 51
Vuosikerta: 21
Numero: 1
Sivujen määrä: 14
eISSN: 1471-2393
DOI: https://doi.org/10.1186/s12884-020-03481-y(external)
Verkko-osoite: https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-020-03481-y(external)
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/53237675(external)
BackgroundSevere early onset (less than 34weeks gestation) intrahepatic cholestasis of pregnancy (ICP) affects 0.1% of pregnant women in Australia and is associated with a 3-fold increased risk of stillbirth, fetal hypoxia and compromise, spontaneous preterm birth, as well as increased frequencies of pre-eclampsia and gestational diabetes. ICP is often familial and overlaps with other cholestatic disorders.Treatment options for ICP are not well established, although there are limited data to support the use of ursodeoxycholic acid (UDCA) to relieve pruritus, the main symptom. Rifampicin, a widely used antibiotic including in pregnant women, is effective in reducing pruritus in non-pregnancy cholestasis and has been used as a supplement to UDCA in severe ICP. Many women with ICP are electively delivered preterm, although there are no randomised data to support this approach.MethodsWe have initiated an international multicentre randomised clinical trial to compare the clinical efficacy of rifampicin tablets (300mg bd) with that of UDCA tablets (up to 2000mg daily) in reducing pruritus in women with ICP, using visual pruritus scores as a measuring tool.DiscussionOur study will be the first to examine the outcomes of treatment specifically in the severe early onset form of ICP, comparing "standard" UDCA therapy with rifampicin, and so be able to provide for the first-time high-quality evidence for use of rifampicin in severe ICP. It will also allow an assessment of feasibility of a future trial to test whether elective early delivery in severe ICP is beneficial.Trial identifiersAustralian New Zealand Clinical Trials Registration Number (ANZCTR): 12618000332224p (29/08/2018). HREC No: HREC/18/WCHN/36.EudraCT number: 2018-004011-44.IRAS: 272398.NHMRC registration: APP1152418 and APP117853.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
